We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Amid growing controversy about the suppression of negative trial results, PhRMA announced it has adopted new voluntary principles to encourage drugmakers to release comprehensive data about clinical trials.
PhRMA has adopted new voluntary principles to encourage drugmakers to release comprehensive data about clinical trials, amid growing controversy about the suppression of negative trial results.
Pharmaceutical companies and other organizations conducting clinical trials are facing a widening array of obstacles on both the regulatory and legal fronts, according to experts who spoke last week at the Drug Information Association's annual meeting in Washington, D.C.
The FDA is looking for ways to increase compliance with a law mandating that companies engaged in clinical trials of drugs for serious or life-threatening diseases post notices about study data on a federal website.
The American Medical Association (AMA) last week approved a proposal calling for HHS to establish a comprehensive registry for clinical trials conducted in the U.S. to ensure that all study results — positive and negative — are publicly available.
Pharmaceutical companies and other organizations conducting clinical trials are facing a widening array of obstacles on both the regulatory and legal fronts, according to experts who spoke yesterday at the Drug Information Association's annual meeting in Washington, D.C.
The American Medical Association (AMA) yesterday approved a proposal calling for HHS to establish a comprehensive registry for clinical trials conducted in the U.S. to ensure that all study results — positive and negative — are publicly available.
Results of the Taxus VI trial indicate that a higher-dose version of Boston Scientific’s paclitaxel-eluting stent is effective in preventing restenosis among high-risk patients, including diabetics.
Guidant revealed Thursday that newly discovered design “issues” could delay development of its highly anticipated Champion stent system by as long as six months.
Medtronic’s efforts to gain ground in the competitive coronary stent market took a hit last week following the release of less-than-favorable trial results for its Endeavor drug-eluting stent system.